Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ChIP-Seq melanoma PDX TM00702

ABSTRACT: ChIP-Seq melanoma PDX TM00702

PROVIDER: PRJNA517652 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8501700.fastq.gz	Fastqsanger.gz
	SRR8501710.fastq.gz	Fastqsanger.gz
	SRR8501701.fastq.gz	Fastqsanger.gz
	SRR8501702.fastq.gz	Fastqsanger.gz
	SRR8501693.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

ChIP-Seq melanoma PDX TM00702

Project description:H3K4me3 ChIP-seq from melanoma PDX tumours fed with different diets

2020-05-18 | GSE125822 | GEO

Patient-derived xenograft platform for metastatic melanoma: RNA sequencing of 4 melanoma PDX samples

Project description:The therapeutic landscape of melanoma is rapidly changing. While targeted inhibitors yield significant responses, their clinical benefit is often limited by the early onset of drug resistance. This motivates the pursuit to establish more durable clinical responses, by developing combinatorial therapies. But while potential new combinatorial targets steadily increase in numbers, they cannot possibly all be tested in patients. Similarly, while genetically engineered mouse melanoma models have great merit, they do not capture the enormous genetic diversity and heterogeneity typical in human melanoma. Furthermore, whereas in vitro studies have many advantages, they lack the presence of micro-environmental factors, which can have a profound impact on tumor progression and therapy response. This prompted us to develop an in vivo model for human melanoma that allows for studying the dynamics of tumor progression and drug response, with concurrent evaluation and optimization of new treatment regimens. Here, we present a collection of patient-derived xenografts (PDX), derived from BRAFV600E, NRASQ61 or BRAFWT/NRASWT melanoma metastases. The BRAFV600E PDX melanomas were acquired both prior to treatment with the BRAF inhibitor vemurafenib and after resistance had occurred, including six matched pairs. We find that PDX resemble their human donors’ melanomas regarding biomarkers, chromosomal aberrations, RNA expression profiles, mutational spectrum and targeted drug resistance patterns. Mutations, previously identified to cause resistance to BRAF inhibitors, are captured in PDX derived from resistant melanomThis melanoma PDX platform represents a comprehensive public resource to study both fundamental and translational aspects of melanoma progression and treatment in a physiologically relevant setting.

2016-05-27 | GSE73737 | GEO

Identification of ChIP-seq and RIME grade antibodies for Estrogen Receptor alpha

Project description:Estrogen Receptor alpha (ERα) is a key driver of most breast cancers, and it is the target of endocrine therapies used in the clinic to treat women with ERα positive (ER+) breast cancer. The two methods ChIP-seq (chromatin immunoprecipitation coupled with deep sequencing) and RIME (Rapid Immunoprecipitation of Endogenous Proteins) have greatly improved our understanding of ERα function during breast cancer progression and in response to anti-estrogens. A critical component of both ChIP-seq and RIME protocols is the antibody that is used to pull down the bait protein. To date, most of the ChIP-seq and RIME experiments for the study of ERα have been performed using the sc-543 antibody from Santa Cruz Biotechnology. However, this antibody has been discontinued, thereby severely impacting the study of ERα in normal physiology as well as diseases such as breast cancer and ovarian cancer. Here, we compare the sc-543 antibody with other commercially available antibodies, and we show that 06-935 (EMD Millipore) and ab3575 (Abcam) antibodies can successfully replace the sc-543 antibody for ChIP-seq and RIME experiments.

2019-03-21 | PXD012930 | Pride

Parallel-factor ER ChIP-seq of Breast Cancer PDX Material

Project description:To demonstrate the versatility of parallel-factor ChIP-seq, we applied our method to the analysis of ER binding in five patient-derived xenograft (PDX) samples.

2018-02-21 | GSE110824 | GEO

RNAseq analysis of transcriptome changes in MM27 metastatic melanoma PDX cells upon treatment with AURKA and/or MEK inhibitors

Project description:Purpose: Study the changes in the transcriptome of metastatic melanoma PDX cells upon combination treatment with AURKA and MEK inhibitors Methods: RNAseq analysis of melanoma PDX cells treated with AURKA inhibitor Alisertib (500nM) and MEK inhibitor trametinib (100nM) for 72 h

2023-07-07 | GSE207645 | GEO

ASCL1 ChIP-seq of patient-derived-xenograft (PDX) GBM lines

Project description:ASCL1 ChIP-seq of patient-derived-xenograft (PDX) GBM lines

| PRJNA639169 | ENA

Parallel-factor ER ChIP-seq of Breast Cancer PDX Material

Project description:Parallel-factor ER ChIP-seq of Breast Cancer PDX Material

| PRJNA434662 | ENA

RNAseq analysis of USP7 knockdown in MM16 and MM27 metastatic melanoma PDX cells

Project description:Purpose: Study of transcriptomic changes upon depletion of USP7 Methods: Melanoma PDX cells were transduced with lentiviral vectors expressing Scrambled(shSCR) or USP7 targeting (shUSP7) shRNA

2022-08-24 | GSE180986 | GEO

ChIP-Chip and SACO Analysis of Pdx-1 binding in NIT-1 Insulinoma Cells

Project description:The BCBC Promoter Chip 5B was used to identify genomic targets of Pdx-1 binding. Genomic DNA from mouse NIT-1 insulinoma cells was immunoprecipitated with a Pdx-1 Antibody, PCR amplified, and labeled to the chip. All hybridizations were versus a common reference sample which was a labeled IgG IP. Additionally a Pdx1 SACO library for NIT-1 cells was generated.

2014-11-21 | E-MTAB-3126 | biostudies-arrayexpress

H3K27Ac ChIP-seq on Patient Dirived Xenograft (PDX) material from one T-cell acute lymphoblastic leukemia (T-ALL) patient.

Project description:ChIP-seq experiment was carried out to characterize enhancers in one T-ALL PDX sample.

2019-12-31 | GSE113565 | GEO